Adenosine diphosphate receptor inhibitor

Adenosine diphosphate (ADP) receptor inhibitor is a class of antiplatelet agents. These drugs inhibit some or all types of adenosine diphosphate receptors (P2Y receptors). P2Y receptors are a family of purinergic G protein-coupled receptors, stimulated by nucleotides such as ATP, ADP, UTP, UDP and UDP-glucose.

Inhibitors of the receptor subtype P2Y12 are one class of P2Y receptor inhibitors. These drugs include clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor, and elinogrel.[1][2][3]


  1. Hashemzadeh, M; Goldsberry, S; Furukawa, M; Khoynezhad, A; Movahed, MR (2009). "ADP receptor-blocker thienopyridines: Chemical structures, mode of action and clinical use. A review". The Journal of invasive cardiology. 21 (8): 406–12. PMID 19652255.
  2. Bauer, Shawn M (2003). "ADP receptor antagonists as antiplatelet therapeutics". Expert Opinion on Emerging Drugs. 8 (1): 93–101. doi:10.1517/14728214.8.1.93. PMID 14610915.
  3. Michelson, AD (2009). "New P2Y12 antagonists". Current Opinion in Hematology. 16 (5): 371–7. doi:10.1097/MOH.0b013e32832ea2f2. PMID 19550317.

This article is issued from Wikipedia - version of the 7/6/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.